Network Meta-analysis on Monthly Migraine Day Reductions With Fremanezumab, Rimegepant, and Atogepant in the Prevention of Episodic Migraine

被引：0
|
作者：
Silberstein, S. D. [1 ]
Cohen, J. M. [2 ]
Driessen, M. [3 ]
Muresan, B. [3 ]
Krasenbaum, L. J. [2 ]
Johnston, A. [4 ]
Seminerio, M. J. [5 ]
Carr, K. [5 ]
Akcicek, H. [3 ]
Dever, J. [4 ]
机构：
[1] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
[2] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[3] Teva Pharmaceut, Amsterdam, Netherlands
[4] Med Decis Modeling, Indianapolis, IN USA
[5] Teva Pharmaceut USA Inc, Parsippany, NJ USA
来源：
CEPHALALGIA | 2021年 / 41卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0471
引用
收藏
页码：266 / 266
页数：1
相关论文
共 50 条
  • [1] Network Meta-analysis on Monthly Migraine Day Reductions With Fremanezumab, Rimegepant, and Atogepant in the Prevention of Episodic Migraine
    Silberstein, S. D.
    Cohen, J. M.
    Driessen, M.
    Muresan, B.
    Krasenbaum, L. J.
    Johnston, A.
    Seminerio, M. J.
    Carr, K.
    Akcicek, H.
    Dever, J.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [2] Rimegepant Versus Atogepant and Monoclonal Antibody Treatments for the Prevention of Migraine: A Systematic Literature Review and Network Meta-analysis
    Popoff, E.
    Powell, L.
    Rahim, T.
    Johnston, K.
    Harris, L.
    Thiry, A.
    Coric, V.
    L'Italien, G.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 122 - 122
  • [3] Rimegepant versus atogepant and monoclonal antibody treatments for the prevention of migraine: A systematic literature review and network meta-analysis
    Popoff, E.
    Powell, L.
    Rahim, T.
    Johnston, K. M.
    Harris, L.
    Thiry, A. C.
    Coric, V
    L'Italien, G. J.
    [J]. HEADACHE, 2021, 61 : 145 - 146
  • [4] Rimegepant Versus Atogepant and Monoclonal Antibody Treatments for the Prevention of Migraine: A Systematic Literature Review and Network Meta-analysis
    Popoff, Evan
    Powell, Lauren
    Johnston, Karissa
    O'Sullivan, Fiona
    Harris, Linda
    Leroue, Chelsea
    Croop, Robert
    Coric, Vlad
    Moren, James
    [J]. NEUROLOGY, 2022, 98 (18)
  • [5] Rimegepant Versus Atogepant and Monoclonal Antibody Treatments for the Prevention of Migraine: A Systematic Literature Review and Network Meta-analysis
    Popoff, E.
    Powell, L.
    Rahim, T.
    Johnston, K.
    Harris, L.
    Thiry, A.
    Coric, V.
    L'Italien, G.
    [J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 181 - 182
  • [6] Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety
    Simona Lattanzi
    Eugen Trinka
    Claudia Altamura
    Cinzia Del Giovane
    Mauro Silvestrini
    Francesco Brigo
    Fabrizio Vernieri
    [J]. Neurology and Therapy, 2022, 11 : 1235 - 1252
  • [7] Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety
    Lattanzi, Simona
    Trinka, Eugen
    Altamura, Claudia
    Del Giovane, Cinzia
    Silvestrini, Mauro
    Brigo, Francesco
    Vernieri, Fabrizio
    [J]. NEUROLOGY AND THERAPY, 2022, 11 (03) : 1235 - 1252
  • [8] Atogepant for the prevention of episodic migraine in adults
    Switzer, Maranda Paige
    Robinson, Joseph Edward
    Joyner, Kayla Rena
    Morgan, Kelsey Woods
    [J]. SAGE OPEN MEDICINE, 2022, 10
  • [9] Reduction in monthly migraine days (MMDs) with fremanezumab and erenumab among patients with episodic migraine (EM) with 24 prior treatment failures: A Network Meta-Analysis
    Mu, Fan
    Patterson-Lomba, Oscar
    Thompson, Stephen
    Gandhi, Sanjay
    Doctor, Tahera
    Cohen, Joshua
    Dua, Akanksha
    Yang, Ronghua
    [J]. JOURNAL OF HEADACHE AND PAIN, 2019, 20
  • [10] Fremanezumab for the prevention of chronic and episodic migraine
    Lionetto, L.
    Cipolla, F.
    Guglielmetti, M.
    Martelletti, P.
    [J]. DRUGS OF TODAY, 2019, 55 (04) : 265 - 276
12345